Promising combo tackles rare blood cancer in chinese patients
NCT ID NCT05673785
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of brentuximab vedotin plus standard chemotherapy (CHP) in 52 Chinese adults with a rare type of lymphoma called CD30+ peripheral T-cell lymphoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants receive the drugs through an IV and oral pills over 21-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone
What this could lead to
If successful, this could provide a new first-line treatment option for Chinese patients with CD30+ peripheral T-cell lymphoma, potentially improving response rates.
What could go wrong
This is a small, single-arm phase 2 trial with no placebo group, so results may not be definitive. Side effects from the chemotherapy combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Cancer Hospital
Hefei, 230088, China
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Chongqing University Cancer Hospital
Chongqing, 400030, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
Fujian Medical University Union Hospital
Fuzhou, 350001, China
-
Guangdong Provincial Peoples Hospital
Guangzhou, 510080, China
-
Henan Cancer Hospital
Zhengzhou, 450003, China
-
Peking University Third Hospital
Beijing, 100191, China
-
Shandong Cancer Hospital
Jinan, 250117, China
-
Shengjing Hospital of China Medical University
Shenyang, 110022, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, 330006, China
-
The First Affiliated Hospital of Soochow University
Suzhou, 215004, China
-
The First Affiliated Hospital of Zhejiang University school of medicine
Hangzhou, 310003, China
-
The First Hospital of Jilin University
Changchun, 130021, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, 300060, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China